Esperion’s Strategic Growth and Global Expansion Drive Buy Rating

H.C. Wainwright analyst Joseph Pantginis has maintained their bullish stance on ESPR stock, giving a Buy rating on June 13.

Joseph Pantginis has given his Buy rating due to a combination of factors, including Esperion’s strategic focus on U.S. growth and geographic expansion. The company has demonstrated strong commercial execution, with a clear strategic plan for 2025 that includes sustained operating profitability and global expansion of its BDA franchise. The U.S. product revenue for NEXLETOL/NEXLIZET showed growth, driven by an increase in retail prescriptions and supported by favorable guidelines from the 2025 ACC/AHA Multi-Society.
Additionally, Esperion’s efforts to position BDA as a preferred treatment over statins and PCSK9 inhibitors are expected to result in accelerated growth. The company’s strong focus on global reach, with approvals in multiple countries and anticipated approvals in Japan and Canada, further supports this outlook. Moreover, the development of new combination products and the expansion of its early-stage pipeline, particularly targeting primary sclerosing cholangitis, highlight Esperion’s commitment to future value creation and lifecycle extension.

Pantginis covers the Healthcare sector, focusing on stocks such as Cytokinetics, Esperion, and Actinium Pharmaceuticals. According to TipRanks, Pantginis has an average return of -20.5% and a 27.15% success rate on recommended stocks.

In another report released on June 13, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $7.00 price target.